Airomir Autohaler 100mcg 200 dose UK

Airomir Autohaler 100mcg 200 dose UK
Click to enlarge
[AIR233S]
Price: only 7.40 (No VAT)
   
 Key Points 
 No prescription?- Just click the green banner above - 'Buy now. Free online consultation.' 
 Totalpharmacy.co.uk is a genuine UK online pharmacy registered with the General Pharmaceutical Council. Registration 9010546. 
 Free Shipping from our UK registered online pharmacy. 
 Buy Now with our online prescriber service. Free consultation. Next day delivery. Discreet and professional service. 
   

Pack price equivalent (1 pack) is 7.40 (No VAT)

You must order the quantity stated on your prescription (or less if you do not need the full quantity)

 
[+] Prescription Only Medicine - Click here for important information.

This product is a prescription-only medication (POM). You cannot order this item unless you have a valid prescription from a UK registered medical practitioner.

The original prescription must be posted to us before we can dispense this drug.

You may download our FREEPOST address label (PDF format) and print your envelope, which will be treated as first class post.

Alternatively, address your envelope:

Freepost RTXUGEBCGGJH
Morton's Total Pharmacy
Ian Morton Ltd
Trinity Square
Axminster
EX13 5AP

Note: If you hand write the address, the envelope will be treated as 2nd class post. For your convenience, we will send you a supply of pre-printed envelopes with your order.

Please order the exact quantity stated on your prescription (or less if you do not need the full quantity)

There is no VAT on prescription-only medications for human use.


Write Review
Twitter
Stumbleupon
Reddit
Pintrest
Newsvine
Linkedin
Google+
Google
Facebook
Digg

Product Details

Airomir Autohaler is available to buy now online. If you don't have a prescription for Airomir Autohaler, click the green banner above 'Buy now' to access our UK online prescriber service. The Airomir Autohaler could be with you as soon as tomorrow from our UK registered online pharmacy.

Airomir Autohaler device is used in the management of bronchial asthma, for the relief of wheezing and shortness of breath used on an as required basis. Airomir Autohaler device may be used as necessary to relieve attacks of acute dyspnoea and may be used prophylactically before exertion or to prevent exercise-induced asthma. Airomir Autohaler device may also be used in the treatment of the reversible component of airways obstruction.

Directions

Adults: For the relief of wheezing, shortness of breath and attacks of acute dyspnoea in patients with asthma, or the reversible component of airways obstruction, one or two inhalations may be administered as a single dose.
For prophylaxis of exercise-induced asthma, two inhalations before exercise.
Children: For the relief of wheezing, shortness of breath and attacks of acute dyspnoea in children with asthma, one inhalation increasing to two if necessary may be administered as a single dose.
For prophylaxis of exercise-induced asthma, one inhalation increasing to two if necessary before exercise.
Elderly: No special dosage recommendations are made for elderly
patients.
For all patients, the maximum recommended dose should not exceed eight inhalations in 24 hours. With repetitive dosing, inhalations should not usually be repeated more often than every 4 hours.

Warnings

Patients should be instructed in the proper use of the inhaler and their technique checked, to ensure that the active substance reaches the target areas within the lungs. The management of asthma should normally follow a stepwise programme, and the patient's response should be monitored clini
cally and by lung function tests. Increasing use of short-acting bronchodilators, in particular 2-agonists to control symptoms, indicates deterioration of asthma control. Under these conditions, the patient's therapy plan should be reassessed. Patients with persistent asthma should receive optimal anti-
inflammatory basic therapy with corticosteroids.
Sudden and progressive deterioration in asthma control is potentially life threatening and consideration should be given to increasing or starting oral and/or inhaler corticosteroid therapy. In patients considered at risk, daily peak flow monitoring may be instituted.
The patient should be advised to seek medical advice if a previously effective dose ceases to be effective for at least three hours, and/or their asthma seems to be worsening.
The dosage or frequency of administration should only be increased on medical advice. Patients requiring long-term management with
Airomir Autohaler device should be kept under regular surveillance.
Salbutamol should be administered cautiously to patients with thyrotoxicosis.
Potentially serious hypokalaemia has been reported in patients taking 2-agonist therapy mainly from parenteral and nebulised administration. Particular caution is advised in patients with severe asthma. Hypokalaemia may also occur in hypoxic patients and those treated with xanthine derivatives, steroids, diuretics and long-term laxatives. Extra care should therefore be taken if 2-agonists are used in these groups of patients and it is recommended that serum potassium levels should be monitored in
such situations.
Care should be taken when treating acute asthma attacks or exacerbation of severe asthma as increased serum lactate levels, and rarely, lactic acidosis have been reported after high doses of salbutamol have been u
sed in emergency situations. This is reversible on reducing the dose of salbutamol.
Unwanted stimulation of cardiac adrenoceptors can occur in patients taking 2-agonist therapy.
Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol.
There is some evidence from post-marketing data and published li
terature of rare occurrences of myocardial ischaemia associated with -agonists. Patients with underlying severe heart disease (e.g. ischaemic heart disease, arrhythmias or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they
may be either respiratory or cardiac in origin.
As with other inhalation therapy, the poten tial for paradoxical bronchospasm should be considered. If this occurs, the Airomir Autohaler should be discontinued immediately and alternative therapy given.
Salbutamol and non-selective -antagonists such as propranolol should not usually be prescribed together.
In common with other -agonists, salbutamol can induce reversible metabolic changes such as increased blood glucose levels. Patients with diabetes may be unable to compensate for the increase in blood glucose and the development of ketoacidosis has been reported. Concurrent administration of
glucocorticoids can exaggerate this effect.
Patients should be warned they may experien ce a different taste on inhalation compared to their previous inhaler.
Severe exacerbations of asthma must be treated in the normal way.

Pack Size

1 pack

More Info ..

To view this product's Patient Information Leaflet, click here.

We Also Recommend :
Airomir Autohaler 100mcg 200 dose UK7.40 (No VAT)
Buy 1 'Airomir Autohaler 100mcg 200 dose UK' now
Airomir Inhaler 100mcg 200 dose UK2.45 (No VAT)
Buy 1 'Airomir Inhaler 100mcg 200 dose UK' now
Ventolin (Salbutamol) Evohaler Inhaler 100mcg -1 UK1.72 (No VAT)
Buy 1 'Ventolin (Salbutamol) Evohaler Inhaler 100mcg -1 UK' now

Friend's email:  
If you would like to tell a friend about this product, enter their e-mail address. You must be logged in to use this feature.